Home » Newsletters » BioWorld Science

BioWorld Science

July 3, 2012

View Archived Issues

Allergan patents novel lysophospholipid receptor ligands

New aminotransferase inhibitors prepared by Pfizer

Phase Ia trial assesses AGS-009 in patients with SLE

Scientists link new mutations to orofacial clefts and cancer risk

Melatonin MT2 receptor agonist shows promise to treat sleep-related disorders

Dainippon Sumitomo Pharma discloses novel anti-CD81 antibodies

Lilly designs new mGlu5 receptor antagonists

Early-stage clinical results disclosed on prodrug for cancer

Esteve divulges novel sigma1-receptor ligands

Mologen enters agreement for MIDGE-based gene therapy

Novel agents for neurodegenerative diseases discovered in Japan

Merck Serono and Compugen form new biomarker company

Janssen submits NDA for tuberculosis drug with new mode of action

NuPathe to resubmit NDA for migraine patch

AstraZeneca and Cellworks to design combination therapies for drug-resistant tuberculosis

The Medicines Company gives update on cangrelor trial enrollment

New diagnostics for cancer prepared by GE Healthcare

Rexahn submits IND application for RNA helicase p68 inhibitor

Momenta Pharmaceuticals begins dosing in metastatic pancreatic cancer study

New compounds for cancer developed in Canada

Milatuzumab evaluated in elderly patients with chronic lymphocytic leukemia

Ono to conduct first-in-human trial of peptide-cocktail cancer vaccine

Enrollment begins in phase III Kyprolis trial

Cerulean updates on its lead nanopharmaceutical anticancer candidate

Zonisamide monotherapy approved in E.U., application for pediatric use under review

FDA issues new drug safety communication regarding Zofran

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...